Latest

5 stories

Hide weekly roundups

Thursday, September 24

Clinical readoutCLN-049 CLN-978 Cullinan Therapeutics Inc.

Cullinan Therapeutics outlines fourth-quarter 2026 data plans across three T cell engager programs

The company plans data updates on CLN-978, velinotamig, and CLN-049 in autoimmune and oncology indications between November and December 2026.

SEC filing

Wednesday, August 12

Clinical readoutCullinan Therapeutics Inc.

Zipalertinib combo hits PFS endpoint in Phase 3 lung cancer trial

Taiho and Cullinan Therapeutics report the REZILIENT3 trial met its primary endpoint at a planned interim analysis, with plans to pursue FDA approval.

SEC filing

Thursday, August 6

Quarterly updateCullinan Therapeutics Inc.

Cullinan reports Q2 2026 results, outlines T cell engager trial timelines

Cullinan says a positive FDA meeting clears the way for a registrational AML study this quarter, with cash runway into 2029.

SEC filing

Friday, July 31

Cullinan Therapeutics registers Phase 1b/2a trial of velinotamig in ITP and wAIHA

Trial updateCullinan Therapeutics Inc.

Thursday, July 23

Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AML

Trial updateazacitidine CLN-049